Refaat Shalaby

2.7k total citations · 1 hit paper
17 papers, 2.2k citations indexed

About

Refaat Shalaby is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Refaat Shalaby has authored 17 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Oncology. Recurrent topics in Refaat Shalaby's work include Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (6 papers) and Glycosylation and Glycoproteins Research (5 papers). Refaat Shalaby is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (6 papers) and Glycosylation and Glycoproteins Research (5 papers). Refaat Shalaby collaborates with scholars based in United States and Canada. Refaat Shalaby's co-authors include Terje Espevik, Anders Waage, Keelung Hong, Christopher C. Benz, Dmitri B. Kirpotin, Demetrios Papahadjopoulos, Ulrik B. Nielsen, James D. Marks, P Brandtzæg and Alfred Halstensen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Nature Biotechnology.

In The Last Decade

Refaat Shalaby

17 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

2002 518 citations John W. Park, Keelung Hong et al. PubMed profile →

Peers

Countries citing papers authored by Refaat Shalaby

Since Specialization

Citations

This map shows the geographic impact of Refaat Shalaby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Refaat Shalaby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Refaat Shalaby more than expected).

Fields of papers citing papers by Refaat Shalaby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Refaat Shalaby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Refaat Shalaby. The network helps show where Refaat Shalaby may publish in the future.

Co-authorship network of co-authors of Refaat Shalaby

This figure shows the co-authorship network connecting the top 25 collaborators of Refaat Shalaby. A scholar is included among the top collaborators of Refaat Shalaby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Refaat Shalaby. Refaat Shalaby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Anti-HER2 Immunoliposomes 2002 ·Clinical Cancer Research ·John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, José Baselga, Yvonne Shao, Ulrik B. Nielsen, James D. Marks, Dan H. Moore, Demetrios Papahadjopoulos, Christopher C. Benz	10
2	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. breakdown → 2002 ·PubMed ·John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, José Baselga, Yvonne Shao, Ulrik B. Nielsen, James D. Marks, Dan H. Moore, Demetrios Papahadjopoulos, Christopher C. Benz	518
3	Genome-wide allelotyping of a new in vitro model system reveals early events in breast cancer progression. 2002 ·PubMed ·Zheng Li, Zhen Meng, Aejaz Sayeed, Refaat Shalaby, Britt‐Marie Ljung, Shanaz H. Dairkee	22
4	Tumor targeting using anti-her2 immunoliposomes 2001 ·Journal of Controlled Release ·(unknown), Dmitri B. Kirpotin, Keelung Hong, Refaat Shalaby, Yang Shao, Ulrik B. Nielsen, James D. Marks, Demetrios Papahadjopoulos, Christopher C. Benz	246
5	A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation 2001 ·Proceedings of the National Academy of Sciences ·Moses M. Kim, (unknown), Inna L. Botchkina, Refaat Shalaby, Ann D. Thor, Elizabeth H. Blackburn	116
6	Alternatively Spliced Products CC3 and TC3 Have Opposing Effects on Apoptosis 2000 ·Molecular and Cellular Biology ·Stephanie Whitman, Xia Wang, Refaat Shalaby, Emma Shtivelman	33
7	Anti‐HER2 Immunoliposomes for Targeted Drug Delivery 1999 ·Annals of the New York Academy of Sciences ·Keelung Hong, Dmitri B. Kirpotin, (unknown), Yi Ming Shao, Refaat Shalaby, (unknown), Christopher C. Benz, Demetrios Papahadjopoulos	17
8	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes 1998 ·Journal of Liposome Research ·Demetrios Papahadjopoulos, Dmitri B. Kirpotin, John W. Park, Keelung Hong, Yi Ming Shao, Refaat Shalaby, Gail Colbern, Christopher C. Benz	15
9	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes 1997 ·Journal of Liposome Research ·Dmitri B. Kirpotin, John W. Park, Keelung Hong, Yi Shao, Refaat Shalaby, Gail Colbern, Christopher C. Benz, Demetrios Papahadjopoulos	24
10	An evaluation of the accuracy of four ELISA methods for measuring natural and recombinant human interferon-g 1996 ·Journal of Immunological Methods ·Brian D. Paasch, B. R. Reed, (unknown), (unknown), Ellen Gilkerson, Refaat Shalaby	5
11	High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli 1996 ·Nature Biotechnology ·Zhenping Zhu, Gerardo Zapata, Refaat Shalaby, Brad Snedecor, Han Chen, Paul Carter	98
12	Development of anti-p185HER2 immunoliposomes for cancer therapy. 1995 ·Proceedings of the National Academy of Sciences ·(unknown), Keelung Hong, Paul Carter, H S Asgari, Li Guo, Guillermo Alberto Keller, (unknown), Refaat Shalaby, Claire E. Kotts, (unknown)	209
13	Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells 1991 ·The Journal of Immunology ·Bjørn Naume, Refaat Shalaby, Werner Lesslauer, Terje Espevik	90
14	Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts 1990 ·European Journal of Immunology ·Anders Waage, Geir Slupphaug, Refaat Shalaby	191
15	Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. 1990 ·The Journal of Experimental Medicine ·Terje Espevik, Manfred Brockhaus, Hansruedi Loetscher, Unni Nonstad, Refaat Shalaby	231
16	The role of TNF in regulation of cell function. 1990 ·PubMed ·Terje Espevik, Refaat Shalaby, Nina‐Beate Liabakk, Anders Waage, Anders Sundan	2
17	Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. 1989 ·The Journal of Experimental Medicine ·Anders Waage, Alfred Halstensen, Refaat Shalaby, P Brandtzæg, Peter Kierulf, Terje Espevik	398

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact